Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Age-specific reference ranges for serum prostate-specific antigen

T D Richardson1, J E Oesterling

  • 1Michigan Prostate Institute, Ann Arbor, USA.

The Urologic Clinics of North America
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

The Journal of urology·1999
Same author

Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

The Journal of urology·1999
Same author

Have complication rates decreased after treatment for localized prostate cancer?

The Journal of urology·1999
Same author

Reference ranges for serum prostate-specific antigen in black and white men without cancer.

Urology·1998
Same author

Understanding artificial neural networks and exploring their potential applications for the practicing urologist.

Urology·1998
Same author

Screening digital rectal examination and prostate cancer mortality: a population-based case-control study.

Urology·1998

Prostate-Specific Antigen (PSA) is the best tumor marker for cancer, with age-specific ranges improving early prostate cancer detection. Understanding PSA levels requires considering patient age and race for accurate interpretation.

Area of Science:

  • Oncology
  • Biochemistry
  • Urology

Background:

  • Prostate-Specific Antigen (PSA) has evolved significantly as a tumor marker for prostate cancer over the past two decades.
  • Initial limitations in PSA's sensitivity and specificity have been better understood, leading to improved clinical utility.
  • Despite limitations in differentiating benign from malignant conditions, PSA remains a crucial marker in cancer biology.

Purpose of the Study:

  • To explore the advancements in the clinical utility of Prostate-Specific Antigen (PSA) as a tumor marker.
  • To highlight the importance of age-specific reference ranges for serum PSA in improving diagnostic accuracy.
  • To discuss the influence of patient race and molecular forms of PSA on diagnostic specificity.

Main Methods:

  • Review of research correlating PSA levels with prostate volume and patient age.

Related Experiment Videos

  • Analysis of studies recommending and supporting age-specific reference ranges for serum PSA.
  • Examination of findings related to different racial groups and molecular forms of PSA.

    • Main Results:

    • Age-specific reference ranges for PSA have been shown to improve sensitivity, aiding in the early diagnosis of organ-confined prostate cancer.
    • Improved specificity in older men remains complex, with a need to determine the clinical significance of undetected prostate cancers.
    • Serum PSA interpretation in 1997 requires consideration of both patient age and race, as values differ across racial groups.
    • Emerging research on different molecular forms of PSA and their ratios shows potential for enhancing diagnostic specificity.

    Conclusions:

    • Utilizing age-specific reference ranges is vital for enhancing the clinical utility of PSA testing for prostate cancer.
    • Further research into PSA's molecular forms and their relationship with age and race is necessary for optimizing its role as a diagnostic tool.
    • While not ideal, PSA, when interpreted with age and race considerations, remains the most valuable tumor marker for prostate cancer in 1997.